Arch Pharmalabs Limited Unlisted Share Price
Arch Pharmalabs Limited unlisted share price is ₹85 per share (indicative, as of 18 Oct 2026). Minimum ticket ₹25,000 (lot of 295 shares), the same for every company. Sector: Consumer. Status: unlisted, no DRHP on record.
All unlisted share prices: dated indicative prices for every company the desk tracks.
Updated 19 Oct 2026, 07:10 IST. Dated dealer references.
BuyUnlistedShares tracks 230 unlisted companies with dated prices; Arch Pharmalabs Limited’s indicative price is ₹85 per share as of 19 Oct 2026, a lot of 295 shares.
Key facts
- Indicative price
- ₹85 per share
- Price as of
- 18 Oct 2026
- Minimum investment
- ₹25,000
- Lot size
- 295 shares
- Sector
- Consumer
- Listing status
- Unlisted
- Settlement
- Demat to demat; terms agreed in writing for each deal
- Last updated
- 19 Oct 2026, 07:10 IST
Indicative and dated. BuyUnlistedShares deals as principal.
Buying at a glance
- Minimum ticket
- ₹25,000
- Price shown
- Indicative, dated 18 Oct 2026
- Delivery
- Shares are credited to your demat account
In plain words
- Lock-in if it lists
- Shares bought before an IPO are generally locked in for six months from the IPO allotment date under SEBI rules. The issue documents set the exact terms.
- Demat
- Yes. ISIN INE182F01017: the shares sit in your own demat account and move demat to demat through NSDL or CDSL.
- IPO status
- Unlisted. No DRHP on record.
Facts only, not a rating or a recommendation.
Compare it against the full unlisted share price list: every company the desk quotes, each with a dated indicative price.
Indicative quote unchanged since 25 Jun 2026 (115 dated quotes); no price movement to chart yet.
Key figures
| Market cap | ₹1,330.08 Cr |
|---|---|
| Minimum investment | ₹25,000 |
| Lot size | 295 |
| P/E ratio | 10.9x |
| ROE | 14.57% |
| Book value | ₹54.16 |
| Face value | ₹10 |
| 52-week high | ₹85 |
| 52-week low | ₹85 |
| ISIN | INE182F01017 |
| Dividend yield | — |
Financials (₹ Cr)
| Metric | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 1,341 | — | — |
| PAT | 122 | — | — |
| EPS (₹) | 7.80 | — | — |
About the company
Arch Pharmalabs Limited is a pharmaceutical manufacturing company focused on producing Active Pharmaceutical Ingredients (APIs) and intermediates, which are key raw materials used in making medicines. The company also offers contract development and manufacturing services (commonly known as CRAMS), supporting global pharma companies across the drug lifecycle—from early-stage development to…
Prices shown are indicative and dated. Unlisted shares are illiquid and values can move sharply.
Registered in Mumbai, Maharashtra.
Registry
- ISIN: INE182F01017
- Depository: NSDL & CDSL
- Listed at: Unlisted
- Price as of: 18 Oct 2026
Company facts
| CIN | U24231MH1993PLC150891 |
|---|---|
| Incorporated | 1993 |
| ISIN | INE182F01017 |
| Face value | ₹10 |
| Depository | NSDL & CDSL |
| Registered office | Unit 101/104, Hyde Park, Saki Vihar Road, Opp. Ansa Industrial Estate, Andheri (E), Mumbai, Maharashtra 400072, India |
| Website | archpharmalabs.com |
| Shares outstanding | 15,64,80,000 |
| Lot size | 295 shares |
| Minimum units | 120 |
| DRHP | Not filed |
Financial statements (₹ Cr)
| Metric | FY21 | FY22 | FY23 | FY23 vs FY22 |
|---|---|---|---|---|
| Revenue | 706 | 1,309 | 1,341 | +2.4% |
| EBITDA | −725 | 177 | 180 | +1.7% |
| EBIT | — | — | 157 | — |
| Finance cost | — | — | 35 | — |
| Profit before tax | 1,869 | 52 | 122 | +134.6% |
| Profit after tax | 1,869 | 52 | 122 | +134.6% |
| EPS (₹) | 123.03 | 3.42 | 7.8 | +128.1% |
| Operating margin | — | — | 13.4% | — |
| Net margin | — | — | 9.1% | — |
| Share capital | — | — | 156.8 | — |
| Reserves & surplus | — | — | 681 | — |
| Net worth | — | — | 837.8 | — |
| Total debt (borrowings) | — | — | 850 | — |
| Fixed assets | — | — | 820 | — |
| Capital work in progress | — | — | 30 | — |
| Investments | — | — | 13 | — |
| Inventory | — | — | 681 | — |
| Trade receivables | — | — | 698 | — |
| Trade payables | — | — | 266 | — |
| Cash from operations | — | — | 42.49 | — |
| Cash from investing | — | — | −1.39 | — |
| Cash from financing | — | — | −41.09 | — |
| Net cash generated | — | — | 0.01 | — |
| Cash at year end | — | — | 2.77 | — |
Key ratios and valuation
| Measure | Value | Basis |
|---|---|---|
| Indicative price | ₹85 | dealer reference, 18 Oct 2026 |
| Market cap | ₹1,330.08 Cr | price × 15,64,80,000 shares |
| P/E | 10.9x | price ÷ EPS ₹7.8 (FY23) |
| P/B | 1.57x | price ÷ book value ₹54.16 |
| EPS | ₹7.8 | per share, FY23 |
| Book value | ₹54.16 | per share, latest books |
| RoE | 14.57% | return on equity, latest FY |
| Debt / equity | 1.01 | latest balance sheet |
| Dividend yield | — | |
| Face value | ₹10 | per share |
| 52-week range | ₹85 (unchanged) | quote unchanged since 25 Jun 2026 |
| Shares outstanding | 15,64,80,000 | per company record |
Shareholding pattern
| Category | Holder | % of equity |
|---|---|---|
| Others | Arch Impex Private Limited | 25.24% |
| Institutions | JM Financial Aseet Reconstruction Company | 35.41% |
| Others | Arch Pharmachem Limited | 13.54% |
| Others | Others | 25.81% |
Institutions 35.41% · Others 64.59%
Management and promoters
| Name | Designation | Experience |
|---|---|---|
| Ajit Kamath | Executive Chairman & MD | 20+ |
| Rajendar Kaimal | Executive Director | 18+ |
Business model
Arch Pharmalabs describes Contract Research and Manufacturing Services (CRAMS) as a growing business vertical. It says its capabilities cover route selection, process development and optimization, analytical development, stability studies, safety studies, scale-up, technology transfer, clinical-trial manufacturing and commercial manufacturing for US and EU regulatory requirements.
The company says it can manage complex reactions at scales from a few grams to several tonnes and has used proprietary bio-catalytic or enzymatic technology to develop a manufacturing route for key advanced intermediates. Arch states that it targets projects from large innovator firms that use customized research and manufacturing services. These projects include work in drug development, customized synthesis of drug intermediates, small-scale API manufacturing for clinical trials, and commercial-scale manufacture of patent-protected APIs.
It also describes custom chemical synthesis and contract manufacturing of on-patent APIs and intermediates as parts of its CRAMS portfolio.
Corporate actions and events
| Date | Type | Detail | Ratio / amount | Source |
|---|---|---|---|---|
| Undated | Other | NCLT Mumbai dismissed the Section 9 petition seeking to initiate CIRP against Arch Pharmalabs Limited as time-barred and not maintainable. (21 Nov 2023) | — | Desk note |
Reports and filings
No filings uploaded yet.
Annual reports
Frequently asked questions
What is the Arch Pharmalabs Limited unlisted share price today?
The indicative over-the-counter reference price is ₹85 per share as of 18 Oct 2026. It is a dated dealer reference, refreshed every working day.
Is Arch Pharmalabs Limited listed on a stock exchange?
Not yet. Arch Pharmalabs Limited changes hands in the unlisted market, over the counter and settle into your demat account through NSDL and CDSL.
What is the minimum investment in Arch Pharmalabs Limited?
The minimum ticket is ₹25,000, the same for every company on the site.
What is the ISIN of Arch Pharmalabs Limited?
INE182F01017. Holdings are settled in demat form through NSDL and CDSL.
How do I buy Arch Pharmalabs Limited unlisted shares?
Send an enquiry with the quantity you have in mind. The desk replies with a dated quote, the paperwork list and the demat steps, and the shares settle demat to demat into your own account.
Is there a lock-in if Arch Pharmalabs Limited lists?
Pre-IPO shareholders other than promoters are generally locked in for six months from the date of IPO allotment under SEBI ICDR regulation 17. The final offer document sets the exact terms.
Sources
- Arch Pharmalabs Limited annual report 2022 · FY 2022 · buyunlistedshares.com
- Arch Pharmalabs Limited annual report 2021 · FY 2021 · buyunlistedshares.com
- Arch Pharmalabs Limited company website · archpharmalabs.com
- BuyUnlistedShares indicative price series for Arch Pharmalabs Limited, dated daily · since 25 Jun 2026 (115 dated quotes) · buyunlistedshares.com
How to cite this page: BuyUnlistedShares, “Arch Pharmalabs Limited unlisted share price”, https://buyunlistedshares.com/unlisted-shares/arch-pharmalabs-limited-unlisted-share, as of 19 Oct 2026.
Other Consumer unlisted shares
- A V Thomas & Co. Limited · ₹12,500
- Anglo French Drugs and Industries · ₹1,075
- Anheuser Busch Inbev India (AB InBev) · ₹555
- Apollo Fashion International · ₹44
- Auckland Jute Co. Limited · ₹189
- Axles India Limited · ₹625
Enquire to buy Arch Pharmalabs Limited · Sell a holding
Indicative reference price, dated. BuyUnlistedShares is India's premium unlisted shares desk, run by Gayatri Financial Synergy LLP. In the market since 2002. Data as of 19 Oct 2026.
Before you buy: guides
- How to evaluate an unlisted company before investing
- How Unlisted Share Prices Are Discovered When There Is No Live Order Book
- The risks of buying unlisted and pre-IPO shares in India
- Unlisted Shares Lock-In Period: What Every Investor Must Know (2026)
- Can an NRI invest in unlisted shares in India?
All unlisted shares · IPO calendar · Research & learning · Send an enquiry · Calculators · Jobs · About · Contact · Privacy · Terms · Disclaimer · Grievance redressal
Guides: Start investing · Evaluate a company · How prices are set · Risks · Lock-in periods · After the IPO · Sell ESOPs · NRI investors · Buybacks · Choosing a platform
BuyUnlistedShares (BUS) · Gayatri Financial Synergy LLP (LLPIN ACU-4678) · SCO-39, 1st Floor, HUDA Market, Sector-7, Faridabad, Haryana 121006 · +91 916-916-59-59
